| Literature DB >> 22187567 |
H Kikuta1, M Shibata, S Nakata, T Yamanaka, H Sakata, K Akizawa, K Kobayashi.
Abstract
Background. The ratio of CA-MRSA in children with impetigo has been increasing in Japan. Methods. Antimicrobial susceptibilities of 136 S. aureus isolates from children with impetigo were studied. Furthermore, molecular epidemiological analysis and virulence gene analysis were performed. Results. Of the 136 S. aureus isolates, 122 (89.7%) were MSSA and 14 (10.3%) were MRSA. Of the 14 MRSA strains, 11 belonged to CC89 (ST89, ST91, and ST2117) and carried diverse types of SCCmec: type II (IIb: 3 strains; unknown subtype: 4 strains), type IVa (2 strains), and unknown type (2 strains). The remaining three strains exhibited CC8 (ST-8)-SCCmec type VIa, CC121 (ST121)-SCCmec type V, and CC5 (ST5)-nontypeable SCCmec element, respectively. None were lukS-PV-lukF-PV gene positive. Gentamicin- and clarithromycin-resistant strains were frequently found in both MRSA and MSSA. Conclusions. PVL-negative CC89-SCCmec type II strains are the most predominant strains among the CA-MRSA strains circulating in the community in Japan.Entities:
Year: 2011 PMID: 22187567 PMCID: PMC3236481 DOI: 10.1155/2011/143872
Source DB: PubMed Journal: Int J Pediatr ISSN: 1687-9740
List of primers.
| Gene | Primer name | Size of product (bp) | Primer sequence (5′→3′) | Reference |
|---|---|---|---|---|
| (1) Detection of virulence gene | [ | |||
|
| luk-PV-1 | ATCATTAGGTAAAATGTCTGGACATGATCCA | ||
| luk-PV-2 | 433 | GCATCAASTGTATTGGATAGCAAAAGC | ||
|
| TST-1 | TTCACTATTTGTAAAAGTGTCAGACCCACT | ||
| TST-2 | 180 | TACTAATGAATTTTTTTATCGTAAGCCCTT | ||
|
| mpETA-1 | ACTGTAGGAGCTAGTGCATTTGT | ||
| mpETA-3 | 190 | TGGATACTTTTGTCTATCTTTTTCATCAAC | ||
|
| mpETB-1 | CAGATAAAGAGCTTTATACACACATTAC | ||
| mpETB-2 | 621 | AGTGAACTTATCTTTCTATTGAAAAACACTC | ||
| (2) SCC | [ | |||
| (i) | ||||
|
| mA1 | TGCTATCCACCCTCAAACAGG | ||
| mA2 | 286 | AACGTTGTAACCACCCCAAGA | ||
| Type 1 |
| AACCTATATCATCAATCAGTACGT | ||
|
| 695 | ATTGCCTTGATAATAGCCITCT | ||
| Type 2 |
| TAAAGGCATCAATGCACAAACACT | ||
|
| 937 | ATTGCCTTGATAATAGCCITCT | ||
| Type 3 |
| AGCTCAAAAGCAAGCAATAGAAT | ||
|
| 1,791 | ATTGCCTTGATAATAGCCITCT | ||
| Type 4 |
| GTATCAATGCACCAGAACTT | ||
|
| 1,287 | TTGCGACTCTCTTGGCGTTT | ||
| type 5 |
| CGTCTATTACAAGATGTTAAGGATAAT | ||
|
| 518 | CCTTTATAGACTGGATTATTCAAAATAT | ||
| (ii) | ||||
|
| ml6 | CATAACTTCCCATTCTGCAGATG | ||
| mA7 | 1,963 | ATATACCAAACCCGACAACTACA | ||
|
| IS7 | ATGCTTAATGATAGCATCCGAATG | ||
| mA7 | 2,827 | ATATACCAAACCCGACAACTACA | ||
|
| mA7 | ATATACCAAACCCGACAACTACA | ||
| IS2(iS-2) | 804 | TGAGGTTATTCAGATATTTCGATGT | ||
| (iii) SCC | ||||
| IIa (II.1) | kdpB2 | TAAACTGTGTCACACGATCCAT | ||
| kdpB1 | 287 | GATTACTTCAGAACCAGGTCAT | ||
| IIb (II.2) | 2b3 | GCTCTAAAAGTTGGATATGCG | ||
| 2b4 | 1,518 | TGGATTGAATCGACTAGAATCG | ||
| IIE (II.3) | 4b3 | AACCAACAGTGGTTACAGCTT | ||
| 4b4 | 726 | CGGATTTTAGACTCATCACCAT | ||
| II.4 | II4-3 | GTACCGCTGAATATTGATAGTGAT | ||
| II4-1 | 2,003 | ACTCTAATCCTAATCACCGAAC | ||
| (iv) SCC | ||||
| IVa (IV.1) | 4al | TTTGAATGCCCTCCATGAATAAAAT | ||
| 4a3 | 458 | AGAAAAGATAGAAGTTCGAAAGA | ||
| IVb (IV.2) | 4b3 | AACCAACAGTGGTTACAGCTT | ||
| 4b4 | 726 | CGGATTTTAGACTCATCACCAT | ||
| IVc (IV.3) | 4c5 | ATCCATTTCTCAGGAGTTAG | ||
| 4c4 | 259 | AGGAAATCGATGTCATTATAA | ||
| IVd (IV.4) | 4d3 | AATTCACCCGTACCTGAGAA | ||
| 4d4 | 1,242 | AGAATGTGGTTATAAGATAGCTA | ||
| (3) Multilocus sequence typing (MLST) | [ | |||
| carbamate kinase ( | arcC-Up | TTGATTCACCAGCGCGTATTGTC | ||
| arcC-Dn | 456 | AGGTATCTGCTTCAATCAGCG | ||
| Shikimate dehydrogenase ( | aroE-Up | ATCGGAAATCCTATTTCACATTC | ||
| aroE-Dn | 456 | GGTGTTGTATTAATAACGATATC | ||
| Glycerol kinase ( | glpF-Up | CTAGGAACTGCAATCTTAATCC | ||
| glpF-Dn | 465 | TGGTAAAATCGCATGTCCAATTC | ||
| Guanylate kinase ( | gmk-Up | ATCGTTTTATCGGGACCATC | ||
| gmk-Dn | 429 | TCATTAACTACAACGTAATCGTA | ||
| Phosphate acetyltransferase | pta-Up | GTTAAAATCGTATTACCTGAAGG | ||
| pta-Dn | 474 | GACCCTTTTGTTGAAAAGCTTAA | ||
| Triosephosphate isomerase ( | tpi-Up | TCGTTCATTCTGAACGTCGTGAA | ||
| tpi-Dn | 402 | TTTGCACCTTCTAACAATTGTAC | ||
| Acetyl coenzyme A acetyltransferase | yqiL-Up | CAGCATACAGGACACCTATTGGC | ||
| yqiL-Dn | 516 | CGTTGAGGAATCGATACTGGAAC |
Age distribution in the 136 patients.
| Age (years) | MSSA | MRSA | Total |
|---|---|---|---|
|
| 13 | 2 | 15 |
| 1–<2 | 19 | 2 | 21 |
| 2–<3 | 16 | 5 | 21 |
| 3–<4 | 16 | 2 | 18 |
| 4–<5 | 15 | 1 | 16 |
| 5–<6 | 17 | 0 | 17 |
| 6–<7 | 15 | 2 | 17 |
| 7–<12 | 11 | 0 | 11 |
|
| |||
| Total | 122 | 14 | 136 |
Molecular characterization of 14 MRSA strains isolated from patients with impetigo.
| Strain | Age | SCC | MLST | Presence of exotoxin genes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SCCmec type |
|
| ST | CC | Allelic profile |
|
|
|
| ||
| T-11 | 1 yr | IIb | 2 | A | 2117 | 89 | 1-310-28-18-18-33-50 | − | − | − | + |
| T-33 | 6 yrs 4 mos | IVa | 2 | B | 91 | 89 | 1-26-28-18-18-54-50 | − | − | − | + |
| T-55 | 2 yrs 6 mos | NT | NT | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-64 | 2 yra 6 mos | IINT | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-71 | 6 yrs 6 mos | IIb | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-79 | 3 yrs 10 mos | IVa | 2 | B | 91 | 89 | 1-26-28-18-18-54-50 | − | − | − | + |
| T-83 | 3 yrs 11 mos | IINT | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-114 | 2 yrs 3 mos | NT | NT | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-119 | 2 yrs 2 mos | NT | NT | A | 5 | 5 | 1-4-1-4-12-1-10 | − | + | − | − |
| T-125 | 4 yrs | V | 5 | C2 | 121 | 121 | 6-5-6-2-7-14-5 | − | − | + | − |
| T-132 | 19 ds | IINT | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-137 | 1 yr 1 mo | IIb | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-139 | 10 ds | IINT | 2 | A | 89 | 89 | 1-26-28-18-18-33-50 | − | − | − | + |
| T-144 | 2 yrs 1 mo | IVa | 2 | B | 8 | 8 | 3-3-1-1-4-4-3 | − | + | − | − |
NT: nontypeable.
Comparison of antimicrobial susceptibilities of MRSA and MSSA.
| Antimicrobial agent | Resistance breakpoint ( | MSSA ( | MRSA ( | ||||
|---|---|---|---|---|---|---|---|
| Range ( | MIC90 ( | Resistance (%) | Range ( | MIC90 ( | Resistance (%) | ||
| MPIPC | 4 | ≦2 | ≦2 | 0 | 4–>8 | >8 | 100 |
| ABPC | 0.5 | ≦0.12 5–>16 | 16 | 71.3 | 4–>16 | >16 | 100 |
| CCL | 16 | 1–16 | 4 | 1.6 | 4–>16 | >16 | 92.9 |
| CDTR | 2* | 0.5 –2 | 1 | 0.8 | 2–>16 | >16 | 100 |
| CAM | 4 | ≦0.125–>16 | >16 | 67.2 | >16 | >16 | 100 |
| CLDM | 1 | ≦0.125–0.25 | 0.25 | 0 | ≦0.125–>16 | >16 | 71.4 |
| FOM | 8** | 0.25–>16 | 16 | 20.5 | 1–>16 | 8 | 14.3 |
| MINO | 8 | ≦0.125–0.25 | ≦0.125 | 0 | ≦0.125–16 | 0.25 | 7.1 |
| GM | 8 | 0.25–>16 | >16 | 54.1 | 1–>16 | >16 | 92.9 |
| VCM | 4 | ≦0.5–1 | 1 | 0 | 1-2 | 1 | 0 |
| NDFX | 4** | ≦0.125–2 | ≦0.125 | 0 | ≦0.125–>16 | ≦0.125 | 7.1 |
| FA | 2** | ≦0.125–>16 | 0.5 | 0.82 | ≦0.125–1 | 0.5 | 0 |
The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI). Susceptibility to antimicrobial drugs for which breakpoints are not determined by CLSI was according to the interpretation criteria of the Japan Society for Chemotherapy (*) or defined in this study (**).
Antimicrobial susceptibilities of 14 MRSA strains.
| Strain | MIC ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MPIPC | ABPC | CCL | CDTR | CAM | CLDM | FOM | MINO | GM | VCM | NDFX | FA | |
| T-11 | >8 | >16 | >16 | >16 | >16 | >16 | 1 | ≦0.125 | >16 | 2 | ≦0.125 | 0.25 |
| T-33 | >8 | 16 | >16 | 4 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-55 | >8 | 16 | >16 | 8 | >16 | >16 | 4 | 0.25 | >16 | 1 | ≦0.125 | 0.25 |
| T-64 | >8 | >16 | >16 | >16 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-71 | >8 | 16 | 16 | 4 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | ≦0.125 |
| T-79 | >8 | 16 | >16 | 4 | >16 | ≦0.125 | 4 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-83 | >8 | 16 | >16 | 4 | >16 | >16 | 2 | 0.25 | >16 | 1 | ≦0.125 | ≦0.125 |
| T-114 | >8 | 16 | >16 | 16 | >16 | >16 | 1 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-119 | >8 | >16 | >16 | >16 | >16 | ≦0.125 | >16 | 16 | >16 | 1 | >16 | 0.5 |
| T-125 | 4 | 4 | 4 | 2 | >16 | 0.25 | 4 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-132 | >8 | 16 | >16 | 16 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | ≦0.125 |
| T-137 | >8 | >16 | >16 | >16 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | 1 |
| T-139 | >8 | 16 | >16 | 16 | >16 | >16 | 2 | ≦0.125 | >16 | 1 | ≦0.125 | 0.25 |
| T-144 | >8 | 16 | >16 | 16 | >16 | ≦0.125 | 8 | ≦0.125 | 1 | 1 | ≦0.125 | 0.25 |